Aug 5, 2020

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers.  ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit...

Aug 5, 2020

Apostolos Stathopoulos, CEO, ERC-Belgium talks about using immunotherapy to treat glioblastoma, the most malignant of all gliomas or brain cancers.  ERC's therapy, which stimulates the patient's immune system to mount an immune response against the tumor cells, has demonstrated a clinically meaningful survival benefit...

Jul 22, 2020

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not...

Jul 22, 2020

Jens Hennecke, Chief Business Officer, SOTIO explains how this biotech company is developing the next generation of immunotherapies with a focus on a new compound called SO-C101 based on the cytokine IL-15, the key cytokine that activates T-cells and NK cells. In clinical trials, this drug, a modified IL-15 does not...

Jun 11, 2020

Sonny Hsiao, CEO, President, and Co-Founder Acepodia Biotech discusses how Acepodia is transforming the cell therapy landscape through a flexible and cost-effective platform that can be used to develop potent treatments for a broad range of indications. Sonny describes how they are applying this technology to enhance...